OmniAb, Inc. - Common Stock (OABI)
3.5600
+0.2500 (7.55%)
OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies
By leveraging its proprietary technologies and platforms, the company aims to generate a diverse array of high-quality antibodies for various therapeutic applications, focusing primarily on areas such as oncology, autoimmune diseases, and infectious diseases. OmniAb collaborates with other biotechnology and pharmaceutical companies to enhance drug discovery processes, ultimately seeking to advance innovative treatments that can address unmet medical needs.
Mighty Minis: 7 Small-Cap Stocks That Punch Above Their Weightinvestorplace.com
While you can likely achieve a higher degree of success with blue chips, for blistering gains, turn to powerful small-cap stocks.
Via InvestorPlace · December 15, 2023
7 of the Best Cheap Stocks to Buy Under $5 in October 2023investorplace.com
While the concept is incredibly risky, those who want to give their portfolio a jolt should consider these best cheap stocks.
Via InvestorPlace · October 26, 2023
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via Benzinga · September 26, 2023
7 Stocks to Buy for 200% Returns This Yearinvestorplace.com
These high return stock investments all have the potential to triple in 2023 based on Wall Street expectations.
Via InvestorPlace · June 13, 2023
OABI Stock Earnings: OmniAb Beats EPS, Beats Revenue for Q2 2024investorplace.com
OABI stock results show that OmniAb beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024investorplace.com
OABI stock results show that OmniAb missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buyingbenzinga.com
Although U.S. stocks closed lower on Monday, there were a few notable insider trades.
Via Benzinga · March 26, 2024
OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023investorplace.com
OABI stock results show that OmniAb beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 20, 2024
Earnings Scheduled For March 20, 2024benzinga.com
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQTIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Via Benzinga · March 20, 2024
Earnings Scheduled For August 10, 2023benzinga.com
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQIDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via Benzinga · August 10, 2023
7 Stocks to Buy for Their Massive Upside Potentialinvestorplace.com
While blue chips are relatively predictable, they’re also boring. For serious gains, you need to check out these stocks to buy now.
Via InvestorPlace · May 18, 2023
Stratasys, Navitas Semiconductor, United Insurance And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
U.S. stocks traded mostly lower, with the Dow Jones dropping around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via Benzinga · May 16, 2023
$1.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buyingbenzinga.com
The Dow Jones closed higher on Monday after recording losses last week. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · May 16, 2023
7 Biotech Stocks With Huge Return Potential for Long-Term Investorsinvestorplace.com
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers.
Via InvestorPlace · April 26, 2023
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023benzinga.com
Via Benzinga · April 21, 2023
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023benzinga.com
Via Benzinga · April 13, 2023
Earnings Scheduled For March 30, 2023benzinga.com
Companies Reporting Before The Bell • Creative Realities (NASDAQCREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via Benzinga · March 30, 2023
7 Biotech Stocks That Could Be the Next Big Thinginvestorplace.com
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Via InvestorPlace · March 15, 2023
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023benzinga.com
Via Benzinga · February 22, 2023
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023benzinga.com
Via Benzinga · February 13, 2023
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Saysbenzinga.com
Credit Suisse initiated coverage on OmniAb Inc (NASDAQOABI) with an Outperform rating and a price target of $13.
Via Benzinga · December 16, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022benzinga.com
Via Benzinga · December 20, 2022